Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a retrospective analysis of real-world data in the Journal of Comparative Effectiveness Research (JCER). The study ...

and high annual cost of therapy. The oral version of Mitsubishi Tanabe's drug was approved by the FDA in May, and is expected to increase the number of patients treated with edaravone, reduce the ...